New procedures more accurate in early diagnosis of GI cancers

May 15, 2005

CHICAGO, IL (May 15, 2005) -- Researchers have developed two new tests that are more accurate than current technologies in the early diagnosis of important gastrointestinal cancers. This research was presented today at Digestive Disease Week® 2005 (DDW), the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

"The most important factor in treating any major cancer or gastrointestinal disorder is early detection and treatment," said Richard Rothstein, M.D., of Dartmouth Medical School. "These researchers are paving the way for the next generation of breakthrough diagnostics and procedures, further helping to improve the quality of life and ultimately save lives."

Serum Proteomic Fingerprints for Diagnosis of Gastric Cancer (Abstract 476)

Although stomach cancer is the world's second most deadly cancer, the medical community has yet to identify a reliable gastric tumor marker that would identify individuals genetically predisposed to cancer or individuals in the early stages of the disease. Researchers from the Chinese University of Hong Kong examined the ability of SELDI ProteinChip technology to accurately diagnose gastric cancer. This tool categorizes proteins and creates a unique "fingerprint" to diagnose cancer. This fingerprint represents a series of protein masses that can be used to differentiate between normal and diseased patient samples. Results of the study have demonstrated that serum proteomic fingerprinting may be a highly accurate diagnostic marker for gastric cancer.

The three-part study consisted of finding potential diagnostic markers and developing and validating a diagnostic model. Researchers analyzed the profiles of 38 gastric cancer patients and 29 healthy control patients and found that the identified fingerprints were significantly more prevalent in the cancer group.

Researchers examined 31 proteomic features and used five with a tumor-specific nature to calculate the accuracy of the diagnostic model. Comparing 40 gastric cancer patients and 20 healthy subjects, results showed that diagnostic gastric cancer was diagnosed 73 percent of the time using this model.

"This type of proteomic profiling may have the capacity to identify novel biomarkers for the screening and early detection of gastric cancer," said Wai K. Leung, M.D., lead study author from the Chinese University of Hong Kong.

Confocal Endomicroscopy as a Novel Method to Diagnose Colitis Associated Neoplasias in Ulcerative Colitis: A Prospective Randomized Trial (Abstract 483)

In treating ulcerative colitis (UC), a chronic inflammation of the large intestine, timely diagnosis of precancerous lesions and colitis-associated colon and rectal tumors (CRC) is of crucial importance. Both are serious and potentially life-threatening complications to UC. Scientists from the University of Mainz in Germany investigated the efficacy of chromoendoscopy (CE) in conjunction with confocal endomicroscopy in the detection and in vivo diagnosis of precancerous lesions and CRC. Chromoendoscopy is the topical application of stains or pigments to improve images during endoscopy. Confocal endomicroscopy is an imaging technique that illustrates intact tissue in significant detail by scanning a laser and restricting the light path. Researchers found that the combination of CE and confocal endomicroscopy is more effective in the monitoring of UC than standard colonoscopy.

Researchers divided 153 patients suffering from long-term UC in clinical remission into two groups, with one group receiving a conventional colonoscopy and the other group receiving a panchromoendoscopy (staining of the entire colon) using 0.1 percent methylene blue, a dye used to highlight tumors, along with an endomicroscopy to detect precancerous lesions and CRC.

With an average examination time of 42 minutes, chromoendoscopy in conjunction with endomicroscopy identified significantly more precancerous lesions than the standard colonoscopy. Chromoendoscopy identified lesions with more accuracy, which allows for more targeted biopsies of relevant lesions and may lead to significant improvements in the clinical management of UC patients.

"Precancerous lesions and colorectal carcinoma are two significant impediments in the monitoring and treatment of ulcerative colitis," said Ralf Kiesslich, M.D., of the University of Mainz. "By using chromoendoscopy in conjunction with confocal endomicroscopy, physicians are able to more effectively diagnose these conditions based on targeted biopsies of potentially cancerous areas. This early detection may help save lives."
-end-
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 14-19, 2005 in Chicago, Illinois. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

American Gastroenterological Association

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.